entertainment -WSS

entertainment

author：hotspot 2025-09-29 22:53:21 - browse：7675

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： New brain studies show LSD's effects on the brain in full color

entertainment

WSS

Readout Newsletter: Merck, J&J, and long Covid

Biotech venture capitalists face new demands from investors

Independent physicians launch a new lobbying group

Independent physicians launch a new lobbying group

Copay coupons to count toward deductibles, after Biden court move

Dewpoint Therapeutics lays off staff after losing partnerships

Wikipedia

entertainment

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

How digital therapeutics firms are pivoting after Pear's bankruptcy

Novavax promises a turnaround & Lilly roils the obesity market

Prior authorization will have to move faster under new Biden rule

Anesthesiologist group: stop taking Ozempic before surgery

Francis Collins on trust in science and how Covid communications failed

Medical leaders decry Supreme Court decision on affirmative action

Parkinson’s finding may lead to tests and, someday, treatments

Medicare details structure of new drug price negotiation program

Why doctors need education on FDA device approval process

entertainment

Dewpoint Therapeutics lays off staff after losing partnerships

Elizabeth Holmes banned from government health programs

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

My yearlong odyssey to get my son’s ADHD medication covered

The surgeon had a dilemma only a Nazi medical text could resolve

eGenesis tests gene

focus

knowledge

entertainment

leisure time